Bruker Corporation — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; comparisons are with the corresponding 2022 periods. Bruker develops and sells scientific instruments and analytical and diagnostic solutions through four segments: BSI BioSpin, BSI CALID, BSI NANO and BEST. Amounts below are in U.S. dollars unless noted.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $742.8 million | $638.9 million | $2,110.0 million | $1,822.3 million |
| Gross profit / margin | $382.8 million / 51.5% | $335.3 million / 52.5% | $1,083.0 million / 51.3% | $939.8 million / 51.6% |
| Operating income / margin | $124.5 million / 16.8% | $131.3 million / 20.6% | $333.4 million / 15.8% | $301.7 million / 16.6% |
| Net income attributable to Bruker | $88.1 million | $88.1 million | $221.7 million | $199.2 million |
| Diluted EPS | $0.60 | $0.59 | $1.50 | $1.33 |
- Q3 revenue rose 16.3%; management reported organic revenue growth of $69.5 million after excluding favorable foreign exchange and acquisitions. Nine-month revenue rose 15.8%, with organic growth of $253.9 million.
- Q3 product revenue was $615.1 million and service and other revenue was $127.7 million. Nine-month amounts were $1,741.8 million and $368.2 million, respectively.
- Q3 segment revenue increased year over year: BioSpin 12.9%, CALID 15.3%, NANO 19.9% and BEST 19.1%. For the nine months, growth was 9.6%, 17.0%, 20.3% and 15.3%, respectively.
- Nine-month segment operating income increased at BioSpin ($123.7 million versus $113.7 million), CALID ($151.6 million versus $146.6 million), NANO ($99.7 million versus $72.2 million) and BEST ($28.1 million versus $21.4 million). Segment margins were mixed; corporate, eliminations and other costs rose to $69.7 million from $52.2 million.
- Nine-month operating cash flow was $144.6 million versus $102.9 million. Capital expenditures were $75.4 million versus $94.6 million, yielding reported free cash flow of $69.2 million versus $8.3 million.
Balance sheet, debt and liquidity
- At September 30, 2023, cash and cash equivalents were $363.6 million, down from $645.5 million at year-end 2022. Cash, cash equivalents and restricted cash totaled $366.9 million.
- Total debt, including finance leases, was $1,219.6 million, broadly unchanged from $1,219.2 million at year-end. Current debt and finance lease obligations were $121.0 million, compared with $18.7 million at year-end; long-term debt was $1,098.6 million.
- Bruker had $599.6 million available under its $600 million revolving credit agreement, with no borrowings outstanding under that facility. It reported compliance with debt covenants and said existing cash and credit facilities should support operating and investing needs for at least the next 12 months.
- Current assets were $2,029.4 million and current liabilities were $1,072.3 million. Inventory increased to $916.0 million from $800.1 million.
- Nine-month investing cash outflow was $289.2 million, primarily reflecting $222.3 million for acquisitions and $75.4 million of capital expenditures. Financing cash outflow was $133.5 million, including $101.9 million of share repurchases and $22.1 million of dividends.
Changes, outlook and risks
- Revenue growth reflected strong demand, pricing and acquisitions; Q3 benefited from approximately $20.9 million of favorable currency effects and $13.5 million from acquisitions. Nine-month results included $37.2 million from acquisitions and approximately $3.4 million of unfavorable currency impact.
- Margins weakened despite higher gross profit. Management attributed pressure to foreign exchange, inflation, product mix and acquisition effects; higher planned sales and marketing and R&D spending also weighed on operating margin. Q3 SG&A and R&D were 23.9% and 9.6% of revenue, versus 22.7% and 8.8% a year earlier.
- Nine-month interest and other expense was $30.1 million, including $18.3 million of strategic investment impairment charges and foreign currency transaction losses. Bruker also recorded a $2.7 million cumulative translation loss associated with substantially liquidating its Russian operations. The impairment and Russian translation loss affected the nine-month comparison.
- Other notable activity included the acquisitions of Biognosys and Zontal and other businesses. On October 2, 2023, after quarter-end, Bruker completed its approximately $121 million acquisition of PhenomeX, renamed Bruker Cellular Analytics, and announced a restructuring plan expected to be substantially completed by the end of 2024.
- Management cited supply shortages and longer lead times, inflation and higher energy and transport costs, geopolitical and trade tensions, customer spending delays, foreign exchange and commodity-price volatility, and potential banking-counterparty exposure as risks. The filing gives no specific full-year revenue or earnings guidance.
- Remaining performance obligations were approximately $2,189.4 million at September 30, 2023. Bruker reported no material litigation accruals and said pending proceedings were not expected to have a material impact, while noting the outcome of a related European patent application remains uncertain.
Investor verification priorities
- Review whether inventory growth and working-capital use convert into cash, and track the durability of the improvement in operating cash flow and free cash flow.
- Assess the drivers of lower gross and operating margins, including currency, inflation, mix, acquisitions and increased investment spending.
- Monitor acquisition integration, contingent and hybrid liabilities, the PhenomeX restructuring and the return on recent acquisition spending.
- Check debt maturities and liquidity, particularly the increase in current debt, alongside planned share repurchases and dividends.
- Follow supply-chain, geopolitical, foreign-exchange, commodity and banking risks, as well as the pending European patent matter and tax uncertainties.